New Data Presented At American Burn Association’s Annual Meeting Support Safety Profile Of RECOTHROM® Thrombin, Topical In Pediatric Patients

 
 


ZymoGenetics, Inc. (NASDAQ:ZGEN), today announced the presentation of safety and immunogenicity data among pediatric burn patients at the 42nd Annual Meeting of the American Burn Association in Boston, MA. The study marks the first dedicated look at the safety and immunogenicity of any stand-alone thrombin in pediatric surgical patients. The investigators concluded that RECOTHROM did not appear to be associated with any treatment-related adverse events when used as an aid to hemostasis in pediatric patients undergoing synchronous burn wound excision and skin grafting…


Go to Source

People who read this also read

Write a Comment

Gravatars are small images that can show your personality. You can get your gravatar for free today!

Copyright © 2010 Procto Med. All rights reserved.